Notícias e Atividades da Sellas Life Sciences

Sellas Life Sciences é uma empresa listada sob o símbolo SLS (CH).

Veja o organograma con seus 10 executivos principais

Biografias mais buscadas da Sellas Life Sciences

• Angelos Stergiou, Chief Executive Officer and Director
• Jane Wasman, Chairman of the Board
• David Scheinberg, Director

Criar um alerta
para seguir os movimentos de executivos da Sellas Life Sciences.

Sellas Life Sciences possui 2.045 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Siemens Healthineers (Alemanha) e Optum (Estados Unidos).

Popular M&A news in Saúde

• Navina acaba de anunciar uma arrecadação de fundos de 55 milhões de dólares. (publicado em 30 de março de 2025).
• Alcon has announced the acquisition of Lensar  (publicado em 25 de março de 2025).
• Mercalis and Mercalis have announced they will merge  (publicado em 18 de março de 2025)..

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Bryan Roberts - Director da Included Health
• Paulo Junqueira Moll - Chief Executive Officer da Rede D'Or Sao Luiz

Saiba mais sobre a indústria do Saúde >

Últimos comunicados de imprensa de Sellas Life Sciences

• SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
• SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
• SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
• SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
• SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
• SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
• SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
• SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
• SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
• SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
• View more press releases Close

Redes sociais sobre Sellas Life Sciences

• Sellas Life Sciences na Wikipedia, Google News e Yahoo Finance
• Sellas Life Sciences na LinkedIn, Twitter e YouTube